Clementia Pharmaceuticals

About:

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders.

Website: https://www.clementiapharma.com

Top Investors: New Enterprise Associates, OrbiMed, RA Capital Management, BDC Venture Capital, Rock Springs Capital

Description:

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.